Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04823741

Acronym

SCITH-MESO

Enrollment

Registered

2021-04-01

Start date

2022-02-11

Completion date

2026-02-11

Last updated

2024-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gene Abnormality, Mesothelioma, Malignant, Pleural Mesothelioma

Keywords

malignant pleural mesothelioma, intra tumoral heterogeneity, genetic abnormalities

Brief summary

Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).

Interventions

GENETICPLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA

All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 95 Years

Healthy volunteers

Inclusion criteria

* age \>18 * suspected MPM requiring VATS biopsy after multidisciplinary oncologic board validation * patient able to understand study objectives and able to give an informed consent * patient affiliated to an healthcare society.

Exclusion criteria

* pregnancy * mental disease, psychiatric disorder * patient under protection regimen

Design outcomes

Primary

Measure	Time frame	Description
For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).	day 1 (day of chirurgie)	For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).

Countries

France

Contacts

Primary ContactJean-Michel MAURY, MD

jean-michel.maury@chu-lyon.fr04.72.35.75.90

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026